These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 30645679)

  • 21. Efficacy and safety of eculizumab in childhood atypical hemolytic uremic syndrome in Japan.
    Ito N; Hataya H; Saida K; Amano Y; Hidaka Y; Motoyoshi Y; Ohta T; Yoshida Y; Terano C; Iwasa T; Kubota W; Takada H; Hara T; Fujimura Y; Ito S
    Clin Exp Nephrol; 2016 Apr; 20(2):265-72. PubMed ID: 26156042
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Is eculizumab efficacious in Shigatoxin-associated hemolytic uremic syndrome? A narrative review of current evidence.
    Keenswijk W; Raes A; Vande Walle J
    Eur J Pediatr; 2018 Mar; 177(3):311-318. PubMed ID: 29288280
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial.
    Fakhouri F; Hourmant M; Campistol JM; Cataland SR; Espinosa M; Gaber AO; Menne J; Minetti EE; Provôt F; Rondeau E; Ruggenenti P; Weekers LE; Ogawa M; Bedrosian CL; Legendre CM
    Am J Kidney Dis; 2016 Jul; 68(1):84-93. PubMed ID: 27012908
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases.
    Fakhouri F; Delmas Y; Provot F; Barbet C; Karras A; Makdassi R; Courivaud C; Rifard K; Servais A; Allard C; Besson V; Cousin M; Châtelet V; Goujon JM; Coindre JP; Laurent G; Loirat C; Frémeaux-Bacchi V
    Am J Kidney Dis; 2014 Jan; 63(1):40-8. PubMed ID: 24021908
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Correction to: Morphological characteristics of chronic total occlusion: predictors of different strategies for long-segment femoral arterial occlusions.
    Wei LM; Zhu YQ; Zhang PL; Liu F; Lu HT; Zhao JG
    Eur Radiol; 2018 Jun; 28(6):2708-2710. PubMed ID: 29318422
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Correction to: "Familial venoms": a thallium intoxication cluster.
    Ratti F; Facchini A; Beck E; Cazzaniga S; Francesconi S; Tedesco C; Terrani A; Ciceri G; Colombo R; Saini M; Petrolini VM; Citerio G
    Intensive Care Med; 2018 Dec; 44(12):2321-2322. PubMed ID: 30374694
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Eculizumab Modifies Outcomes in Adults with Atypical Hemolytic Uremic Syndrome with Acute Kidney Injury.
    Cao M; Leite BN; Ferreiro T; Calvo M; Fernández C; Alonso Á; Rodriguez A; Salvador P; Seijo R; Pita S; Arjona E; Rodríguez de Córdoba S; Valdés Cañedo F
    Am J Nephrol; 2018; 48(3):225-233. PubMed ID: 30205388
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.
    Ito S; Hidaka Y; Inoue N; Kaname S; Kato H; Matsumoto M; Miyakawa Y; Mizuno M; Okada H; Shimono A; Matsuda T; Maruyama S; Fujimura Y; Nangaku M; Kagami S
    Clin Exp Nephrol; 2019 Jan; 23(1):112-121. PubMed ID: 30039480
    [TBL] [Abstract][Full Text] [Related]  

  • 29. When to Stop Eculizumab in Complement-Mediated Thrombotic Microangiopathies.
    Olson SR; Lu E; Sulpizio E; Shatzel JJ; Rueda JF; DeLoughery TG
    Am J Nephrol; 2018; 48(2):96-107. PubMed ID: 30110670
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Atypical hemolytic uremic syndrome with C3 p.I1157T missense mutation successfully treated with eculizumab].
    Okano M; Matsumoto T; Nakamori Y; Ino K; Miyazaki K; Fujieda A; Sugimoto Y; Tawara I; Yamaguchi M; Ohishi K; Miwa H; Masuya M; Wada H; Katayama N
    Rinsho Ketsueki; 2018; 59(2):178-181. PubMed ID: 29515070
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Correction to: Genetic Diversity Among Genogroup II Noroviruses and Progressive Emergence of GII.17 in Wastewaters in Italy (2011-2016) Revealed by Next-Generation and Sanger Sequencing.
    Suffredini E; Iaconelli M; Equestre M; Valdazo-González B; Ciccaglione AR; Marcantonio C; Della Libera S; Bignami F; La Rosa G
    Food Environ Virol; 2018 Jun; 10(2):222-223. PubMed ID: 29728976
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Correction to: Induced membrane maintains its osteogenic properties even when the second stage of Masquelet's technique is performed later.
    Gindraux F; Loisel F; Bourgeois M; Oudina K; Melin M; de Billy B; Sergent P; Leclerc G; Petite H; Auber F; Obert L; Pluvy I
    Eur J Trauma Emerg Surg; 2020 Apr; 46(2):313-315. PubMed ID: 31667537
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correction to: Real‑world experience with dalbavancin therapy in gram‑positive skin and soft tissue infection, bone and joint infection.
    Tobudic S; Forstner C; Burgmann H; Lagler H; Steininger C; Traby L; Vossen MG; Winkler S; Thalhammer F
    Infection; 2020 Feb; 48(1):149. PubMed ID: 31741186
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Plasma resistant atypical hemolytic uremic syndrome associated with a CFH mutation treated with eculizumab: a case report.
    Sevinc M; Basturk T; Sahutoglu T; Sakaci T; Koc Y; Ahbap E; Akgol C; Kara E; Brocklebank V; Goodship TH; Kavanagh D; Unsal A
    J Med Case Rep; 2015 Apr; 9():92. PubMed ID: 25925370
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Correction to: Routine Sildenafil Does Not Improve Clinical Outcomes After Fontan Operation.
    Collins JLG; Law MA; Borasino S; Erwin WC; Cleveland DC; Alten JA
    Pediatr Cardiol; 2018 Mar; 39(3):644-645. PubMed ID: 29372280
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Correction to: Reduced Foxo3a, FoxL2, and p27 mRNA expression in human ovarian tissue in premature ovarian insufficiency.
    Thanatsis N; Kaponis A; Koika V; Georgopoulos NA; Decavalas GO
    Hormones (Athens); 2019 Dec; 18(4):537-538. PubMed ID: 31912384
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sensitive, reliable and easy-performed laboratory monitoring of eculizumab therapy in atypical hemolytic uremic syndrome.
    Volokhina EB; van de Kar NC; Bergseth G; van der Velden TJ; Westra D; Wetzels JF; van den Heuvel LP; Mollnes TE
    Clin Immunol; 2015 Oct; 160(2):237-43. PubMed ID: 26111482
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and effectiveness of eculizumab for adult patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.
    Kato H; Miyakawa Y; Hidaka Y; Inoue N; Ito S; Kagami S; Kaname S; Matsumoto M; Mizuno M; Matsuda T; Shimono A; Maruyama S; Fujimura Y; Nangaku M; Okada H
    Clin Exp Nephrol; 2019 Jan; 23(1):65-75. PubMed ID: 29959568
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improved renal recovery in patients with atypical hemolytic uremic syndrome following rapid initiation of eculizumab treatment.
    Walle JV; Delmas Y; Ardissino G; Wang J; Kincaid JF; Haller H
    J Nephrol; 2017 Feb; 30(1):127-134. PubMed ID: 26995002
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of Eculizumab in Atypical Hemolytic Uremic Syndrome, Complicating Systemic Lupus Erythematosus.
    Bermea RS; Sharma N; Cohen K; Liarski VM
    J Clin Rheumatol; 2016 Sep; 22(6):320-3. PubMed ID: 27556240
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.